Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Comparing Efficacy and Safety of LY01011 and Xgeva®(Denosumab) in Patients With Bone Metastases From Solid Tumors

NCT04859569 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.

NCT NCT04859569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04859569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Comparing Efficacy and Safety of LY01011 and Xgeva®(Denosumab) in Patients With Bone Metastases From Solid Tumors
Lead sponsor
Luye Pharma Group Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2021
Completion date
June 30, 2023
Enrollment
850 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases from solid tumors